Join Growin Stock Community!

Grifols, s.a.GRFS.US Overview

US StockHealthcare
(No presentation for GRFS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GRFS AI Insights

GRFS Overall Performance

GRFS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GRFS Recent Performance

-1.54%

Grifols, s.a.

0.05%

Avg of Sector

-0.31%

S&P500

GRFS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GRFS Key Information

GRFS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GRFS Profile

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Price of GRFS

GRFS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GRFS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.44
PE Ratio (TTM)
13.81
Forward PE
17.42
PS Ratio (TTM)
1.00
PB Ratio
1.00
Price-to-FCF
9.03
METRIC
VALUE
vs. INDUSTRY
Gross Margin
39.46%
Net Margin
4.96%
Revenue Growth (YoY)
7.31%
Profit Growth (YoY)
8.44%
3-Year Revenue Growth
6.57%
3-Year Profit Growth
10.31%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.44
PE Ratio (TTM)
13.81
Forward PE
17.42
PS Ratio (TTM)
1.00
PB Ratio
1.00
Price-to-FCF
9.03
Gross Margin
39.46%
Net Margin
4.96%
Revenue Growth (YoY)
7.31%
Profit Growth (YoY)
8.44%
3-Year Revenue Growth
6.57%
3-Year Profit Growth
10.31%

  • When is GRFS's latest earnings report released?

    The most recent financial report for Grifols, s.a. (GRFS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GRFS's short-term business performance and financial health. For the latest updates on GRFS's earnings releases, visit this page regularly.

  • Where does GRFS fall in the P/E River chart?

    According to historical valuation range analysis, Grifols, s.a. (GRFS)'s current price-to-earnings (P/E) ratio is 11.37, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of GRFS?

    According to the latest financial report, Grifols, s.a. (GRFS) reported an Operating Profit of 383.27M with an Operating Margin of 20.55% this period, representing a growth of 20.89% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GRFS's revenue growth?

    In the latest financial report, Grifols, s.a. (GRFS) announced revenue of 1.87B, with a Year-Over-Year growth rate of 4.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does GRFS have?

    As of the end of the reporting period, Grifols, s.a. (GRFS) had total debt of 9.72B, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GRFS have?

    At the end of the period, Grifols, s.a. (GRFS) held Total Cash and Cash Equivalents of 622.95M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GRFS go with three margins increasing?

    In the latest report, Grifols, s.a. (GRFS) achieved the “three margins increasing” benchmark, with a gross margin of 40.29%%, operating margin of 20.55%%, and net margin of 6.81%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GRFS's profit trajectory and future growth potential.

  • Is GRFS's EPS continuing to grow?

    According to the past four quarterly reports, Grifols, s.a. (GRFS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GRFS?

    Grifols, s.a. (GRFS)'s Free Cash Flow (FCF) for the period is 255.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 18.57% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GRFS?

    The latest valuation data shows Grifols, s.a. (GRFS) has a Price-To-Earnings (PE) ratio of 11.37 and a Price/Earnings-To-Growth (PEG) ratio of 0.97. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.